ANI Pharmaceuticals, Inc. (ANIP)
After hours:
| Previous close | 66.52 |
| Open | 66.96 |
| Bid | 66.89 x 100 |
| Ask | 67.28 x 100 |
| Day's range | 66.78 - 67.87 |
| 52-week range | 37.87 - 70.81 |
| Volume | |
| Avg. volume | 145,387 |
| Market cap | 1.408B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 78.95 |
| EPS (TTM) | 0.85 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 79.80 |
ZacksModerna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
GlobeNewswireANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event Date:Tuesday, May 14, 2024 Time:12:15pm ET To schedule a 1x1 meeting with management, please contact kristen.patrick@capitalone.com H.C. Wa
ZacksGSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
